Hepatocellular carcinoma future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{CMG}} {{Hepatocellular carcinoma}} ==Overview== ==Future directions== Current research includes the search for the genes that are disregulated in HCC,<ref>[http://web...." |
m Bot: Removing from Primary care |
||
| (5 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Hepatocellular carcinoma}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Future directions== | ==Future directions== | ||
Current research includes the search for the [[gene]]s that are disregulated in HCC,<ref>[http://web.archive.org/web/20060503035140/http://liver.stanford.edu/index2.asp?lang=eng&page=res_recpub Genetic research in HCC] Stanford Asian Liver Center</ref> [[protein]] markers<ref> [http://www.hmri.org/HMRI_News/Resources/newsletter_May_05.pdf Huntington Medical Research Institute News, May 2005]</ref>, and other predictive biomarkers.<ref>[http://www.jco.org/content/vol23/issue11/] ''Journal of Clinical Oncology'', Special Issue on Molecular Oncology: Receptor-Based Therapy, April 2005</ref><ref name=Lau_1999>{{cite journal |author=Lau W, Leung T, Ho S, Chan M, Machin D, Lau J, Chan A, Yeo W, Mok T, Yu S, Leung N, Johnson P |title=Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial |journal=Lancet |volume=353 |issue=9155 |pages=797-801 |year=1999 |pmid=10459961}}</ref> As similar research is yielding results in various other malignant diseases, it is hoped that identifying the aberrant genes and the resultant [[protein]]s could lead to the identification of pharmacological interventions for HCC.<ref name=Thomas_2005>{{cite journal |author=Thomas M, Zhu A |title=Hepatocellular carcinoma: the need for progress |journal=J Clin Oncol |volume=23 |issue=13 |pages=2892-9 |year=2005 |url=http://www.jco.org/cgi/content/full/23/13/2892 |pmid=15860847}}</ref> | Current research includes the search for the [[gene]]s that are disregulated in HCC,<ref>[http://web.archive.org/web/20060503035140/http://liver.stanford.edu/index2.asp?lang=eng&page=res_recpub Genetic research in HCC] Stanford Asian Liver Center</ref> [[protein]] markers<ref> [http://www.hmri.org/HMRI_News/Resources/newsletter_May_05.pdf Huntington Medical Research Institute News, May 2005]</ref>, and other predictive biomarkers.<ref>[http://www.jco.org/content/vol23/issue11/] ''Journal of Clinical Oncology'', Special Issue on Molecular Oncology: Receptor-Based Therapy, April 2005</ref><ref name=Lau_1999>{{cite journal |author=Lau W, Leung T, Ho S, Chan M, Machin D, Lau J, Chan A, Yeo W, Mok T, Yu S, Leung N, Johnson P |title=Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial |journal=Lancet |volume=353 |issue=9155 |pages=797-801 |year=1999 |pmid=10459961}}</ref> As similar research is yielding results in various other malignant diseases, it is hoped that identifying the aberrant genes and the resultant [[protein]]s could lead to the identification of pharmacological interventions for HCC.<ref name=Thomas_2005>{{cite journal |author=Thomas M, Zhu A |title=Hepatocellular carcinoma: the need for progress |journal=J Clin Oncol |volume=23 |issue=13 |pages=2892-9 |year=2005 |url=http://www.jco.org/cgi/content/full/23/13/2892 |pmid=15860847}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Disease]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Types of cancer]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Hepatology]] | |||
[[Category:Emergency medicine]] | |||
Latest revision as of 22:08, 29 July 2020
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma future or investigational therapies |
|
FDA on Hepatocellular carcinoma future or investigational therapies |
|
CDC on Hepatocellular carcinoma future or investigational therapies |
|
Hepatocellular carcinoma future or investigational therapies in the news |
|
Blogs on Hepatocellular carcinoma future or investigational therapies |
|
Risk calculators and risk factors for Hepatocellular carcinoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Overview
Future directions
Current research includes the search for the genes that are disregulated in HCC,[1] protein markers[2], and other predictive biomarkers.[3][4] As similar research is yielding results in various other malignant diseases, it is hoped that identifying the aberrant genes and the resultant proteins could lead to the identification of pharmacological interventions for HCC.[5]
References
- ↑ Genetic research in HCC Stanford Asian Liver Center
- ↑ Huntington Medical Research Institute News, May 2005
- ↑ [1] Journal of Clinical Oncology, Special Issue on Molecular Oncology: Receptor-Based Therapy, April 2005
- ↑ Lau W, Leung T, Ho S, Chan M, Machin D, Lau J, Chan A, Yeo W, Mok T, Yu S, Leung N, Johnson P (1999). "Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial". Lancet. 353 (9155): 797–801. PMID 10459961.
- ↑ Thomas M, Zhu A (2005). "Hepatocellular carcinoma: the need for progress". J Clin Oncol. 23 (13): 2892–9. PMID 15860847.